Alveron Pharma Closes €5M Seed Extension Financing
Summary
Alveron Pharma, a Nijmegen, the Netherlands-based company advancing a synthetic anticoagulant and platelet inhibitor reversal agent, raised €5M in Seed extension funding. The company intends to use the funds to advance its innovative drug, OKL-1111, for the treatment of intracranial haemorrhage (ICH). Founded in 2019 and led by CEO Ben Nichols, Alveron Pharma is developing a synthetic anticoagulant and platelet inhibitor reversal agent to prevent haematoma expansion and improve clinical outcomes in patients with ICH. OKL-1111 has a universal mode of action by binding to a downstream clotting factor, enabling administration within 10 minutes of a diagnosing CT scan. In addition, the drug reverses the effects of clopidogrel, a major platelet inhibitor, for which there is currently no antidote.